CAVEATS IN INTERPRETING AND COMPARING LONG-TERM EFFICACY IN BIOLOGIC STUDIES FOR MODERATE-TO-SEVERE PLAQUE PSORIASIS

被引：0
|
作者：
Langley, Richard G. [1 ]
Egeberg, Alexander [2 ]
Gooderham, Melinda [3 ,4 ]
Bissonnette, Robert [5 ]
Ringuet, Julien [6 ]
Kalia, Sunil [7 ]
Park-Wyllie, Laura [8 ]
Abbarin, Nastaran [8 ]
Tran, Diana [9 ]
Zara, Anthony [9 ]
Yang, Ya-Wen [10 ]
Strober, Bruce [11 ,12 ]
机构：
[1] Dalhousie Univ, Halifax, NS, Canada
[2] Bispebjerg Hosp, Copenhagen, Denmark
[3] SKiN Ctr Dermatol & Prob Med Res, Kingston, ON, Canada
[4] Queens Univ, Kingston, ON, Canada
[5] Innovaderm Res Inc, Montreal, PQ, Canada
[6] Ctr Rech Dermatol Quebec Metropolitain CRDQ, Quebec City, PQ, Canada
[7] Univ British Columbia, Vancouver, BC, Canada
[8] Janssen Inc, Toronto, ON, Canada
[9] EVERSA NA, Burlington, ON, Canada
[10] Johnson & Johnson, Janssen Pharmaceut Co, Titusville, NJ USA
[11] Cent Connecticut Dermatol Res, Cromwell, CT USA
[12] Yale Univ, New Haven, CT USA
来源：
ACTA DERMATO-VENEREOLOGICA | 2024年 / 104卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P-031
引用
收藏
页数：102
相关论文
共 50 条
  • [31] The management of moderate-to-severe chronic plaque psoriasis
    Tonini, Annalisa
    Panduri, Salvatore
    D'Erme, Angelo M.
    Papadia, Francesca
    Romaneli, Marco
    Krueger, James G.
    Chiricozzi, Andrea
    GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA, 2017, 152 (05): : 447 - 457
  • [32] Advances in the treatment of moderate-to-severe plaque psoriasis
    Herrier, Richard N.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2011, 68 (09) : 795 - 806
  • [33] Guselkumab for the treatment of moderate-to-severe plaque psoriasis
    Yang, Eric J.
    Sanchez, Isabelle M.
    Beck, Kristen
    Sekhon, Sahil
    Wu, Jashin J.
    Bhutani, Tina
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2018, 11 (04) : 333 - 344
  • [34] Guselkumab in the treatment of moderate-to-severe plaque psoriasis
    Lopez-Sanchez, Cristina
    Puig, Lluis
    IMMUNOTHERAPY, 2020, 12 (06) : 355 - 371
  • [35] Tildrakizumab: A Review in Moderate-to-Severe Plaque Psoriasis
    James E. Frampton
    American Journal of Clinical Dermatology, 2019, 20 : 295 - 306
  • [36] Long-term efficacy and safety of brodalumab in moderate-to-severe plaque psoriasis: a post hoc pooled analysis of AMAGINE-2 and-3
    Reich, K.
    Iversen, L.
    Puig, L.
    Lambert, J.
    Mrowietz, U.
    Saday, K. Kaplan
    Warren, R. B.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2022, 36 (08) : 1275 - 1283
  • [37] Long-term outcomes of ustekinumab in patients with moderate-to-severe psoriasis in a university hospital
    Ossorio-Garcia, Lidia
    Collantes-Rodriguez, Cristina
    Jimenez-Gallo, David
    Linares-Barrios, Mario
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB179 - AB179
  • [38] LONG-TERM EFFICACY OF TRALOKINUMAB IN ADOLESCENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
    Wollenberg, Andreas
    Paller, Amy S.
    Bewley, Anthony
    Cork, Michael
    Hong, Chih-Ho
    Soong, Weily
    Oland, Christian Bjerregard
    Taveira, Christian Moreira
    Gjerum, Le
    Blauvelt, Andrew
    ACTA DERMATO-VENEREOLOGICA, 2023, 103 : 54 - 54
  • [39] Long-Term Benefit-Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis
    Armstrong, April W.
    Soliman, Ahmed M.
    Betts, Keith A.
    Wang, Yan
    Gao, Yawen
    Stakias, Vassilis
    Puig, Luis
    DERMATOLOGY AND THERAPY, 2022, 12 (01) : 167 - 184
  • [40] Long-term safety of ustekinumab in paediatric patients with moderate-to-severe plaque psoriasis: results from an ongoing observational study
    Mahe, Emmanuel
    Geldhof, Anja
    Movshovich, Evgenia
    Schreiber, Joerg
    Malynn, Sandra
    Efficace, Michela
    Seyger, Marieke M. B.
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 189 (03) : E43 - E43
12345